Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.

ABSTRACT: While cancer immune therapy has revolutionized the treatment of metastatic disease across a wide range of cancer diagnoses, a major limiting factor remains with regard to relying on adequate homing of anti-tumor effector cells to the tumor site both prior to and after therapy. Adoptive cell transfer (ACT) of autologous T cells have improved the outlook of patients with metastatic melanoma. Prior to the approval of checkpoint inhibitors, this strategy was the most promising. However, while response rates of up to 50% have been reported, this strategy is still rather crude. Thus, improvements are needed and within reach. A hallmark of the developing tumor is the evasion of immune destruction. Achieved through the recruitment of immune suppressive cell subsets, upregulation of inhibitory rece

SUBMITTER: Idorn M 

PROVIDER: S-EPMC6115859 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature